Mode
Text Size
Log in / Sign up
N/A N=133 Treatment

Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence

Overactive Bladder · Urge Incontinence · Incontinence, Urinary · Urinary Urge Incontinence

Enrolled (actual)
133
Serious AEs
3.0%
Results posted
Jul 2021
Primary outcome: Primary: Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary. — 68 percentage of participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
eCoin Tibial Nerve Stimulation (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Valencia Technologies Corporation
Primary completion
Apr 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
67
PRIMARY
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.
16
SECONDARY
Moderate-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events.
14
SECONDARY
Moderate-term Effectiveness Data. Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
69
SECONDARY
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary
78
SECONDARY
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
67
SECONDARY
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
67
SECONDARY
Percentage of Subjects Experiencing 50% or Better Improvement in Urgency Urinary Incontinence Episodes as Measured by a 3-day Voiding Diary.
67
SECONDARY
Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events.
20
SECONDARY
Long-term Safety in All Patients: Percentage of Patients With Device Related Adverse Events
20
SECONDARY
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events
23
SECONDARY
Long-term Safety in All Patients. Percentage of Patients With Device Related Adverse Events
23

Summary

This trial is a prospective, multicenter, single-arm study of the safety and effectiveness of eCoinTM tibial nerve stimulation in subjects having overactive bladder (OAB) with urgency urinary incontinence (UUI). The study will evaluate changes from baseline in OAB symptoms as measured by voiding diaries and patient reported-outcomes through 48 weeks of eCoinTM therapy or 52 weeks of implantation.

Eligibility Criteria

Primary Inclusion Criteria:

  • Women and men between 18 and 80 years old.
  • Diagnosis of overactive bladder with urgency urinary incontinence or mixed urge and stress incontinence with a predominant urgency component (selfreported), for at least 6 months.
  • Individual is without pharmacological treatment of overactive bladder (antimuscarinics and beta-3 agonists).
  • Individual is intolerant of or has an inadequate response to any of anticholinergics, β3-adrenoceptor agonists, onabotulinumtoxinA, or percutaneous tibial nerve stimulation.

Primary Exclusion Criteria:

  • Predominant stress urinary incontinence with more than 1/3 stress urinary incontinent episodes when compared to total urinary incontinent episodes.
  • Clinically significant bladder outlet obstruction.
  • Clinically significant pelvic organ prolapse beyond the hymenal ring.
  • Inadequate skin integrity or any evidence of an infection or inflammation in either lower leg.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03556891). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search